Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review-Reference-Cited by-同舟云学术

Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review

Published:2020-11-11 Issue:5 Volume:22 Page:611-620
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Ritondo Beatrice Ludovica¹,Puxeddu Ermanno¹,Calzetta Luigino²^ORCID,Cazzola Mario¹^ORCID,Rogliani Paola¹^ORCID

Affiliation:

1. Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy

2. Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy

Funder

funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2020.1845314

Reference38 articles.

1. GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD – 2020 Report. 2020 [cited 2020 July 30]. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf

Compliance of Pharmacotherapy with GOLD Guidelines: A Longitudinal Study in Patients with COPD

3. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis

4. Triple therapy trials in COPD: a precision medicine opportunity

5. The effective treatment of COPD: Anticholinergics and what else?

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhaled corticosteroids in severe COPD patients with cardiovascular diseases. Authors’ reply;European Journal of Internal Medicine;2024-08

2. COPD – eine unterschätzte Erkrankung;Praxis;2023-06

3. May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?;Pulmonary Pharmacology & Therapeutics;2022-12

4. The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;Life;2022-01-25

5. Beyond Dual Bronchodilation – Triple Therapy, When and Why;International Journal of Chronic Obstructive Pulmonary Disease;2022-01